DB-2304
Phase 2Small molecule
DB-2304 is one of 28 small molecule programs targeting Phase 1. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
52 competitors in Phase 1
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Erbitux
IImclone
Phase 2
Rayos
RRoxane Laboratories
Phase 2
Navitoclax
AbbViePhase 2
Fludara
SanofiPhase 1
Yervoy
Bristol-Myers SquibbPhase 1
Benznidazole
CCorestemchemon, Inc.
Phase 1
VX-407
Vertex PharmaceuticalsPhase 1
Radiprodil
GGRIN Therapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DB-2304. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDualityBio Inc.